RSCM
MIRM icon

Rock Springs Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Rock Springs Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.4M Sell
798,145
-13,149
-2% -$1.32M 4.56% 5
2026
Q1 		$74.9M Buy
811,294
+49,000
+6% +$4.61M 4.42% 4
2025
Q4 		$60.2M Buy
762,294
+1,168
+0.2% +$83.8K 3.09% 8
2025
Q3 		$55.8M Sell
761,126
-57,080
-7% -$3.63M 3.26% 7
2025
Q2 		$41.6M Sell
818,206
-133,559
-14% -$5.95M 2.59% 10
2025
Q1 		$42.9M Sell
951,765
-519,799
-35% -$24.5M 2.45% 12
2024
Q4 		$60.8M Sell
1,471,564
-108,924
-7% -$4.54M 2.32% 11
2024
Q3 		$61.6M Sell
1,580,488
-191,550
-11% -$7.64M 2.01% 12
2024
Q2 		$60.6M Sell
1,772,038
-84,526
-5% -$2.22M 1.82% 14
2024
Q1 		$46.6M Buy
1,856,564
+5,100
+0.3% +$140K 1.18% 31
2023
Q4 		$54.7M Buy
1,851,464
+30,731
+2% +$930K 1.35% 24
2023
Q3 		$57.5M Hold
1,820,733
– – 1.54% 22
2023
Q2 		$47.1M Buy
1,820,733
+25,000
+1% +$665K 1.12% 30
2023
Q1 		$43.1M Hold
1,795,733
– – 1.03% 32
2022
Q4 		$35M Hold
1,795,733
– – 0.84% 42
2022
Q3 		$37.7M Buy
1,795,733
+78,000
+5% +$1.88M 0.97% 38
2022
Q2 		$33.4M Buy
1,717,733
+51,525
+3% +$1.22M 0.97% 36
2022
Q1 		$36.7M Buy
1,666,208
+127,394
+8% +$2.6M 0.92% 37
2021
Q4 		$24.5M Buy
1,538,814
+13,191
+0.9% +$205K 0.57% 56
2021
Q3 		$30.4M Buy
1,525,623
+1,900
+0.1% +$30.9K 0.64% 51
2021
Q2 		$26.3M Buy
1,523,723
+20,923
+1% +$375K 0.52% 58
2021
Q1 		$29.8M Buy
1,502,800
+6,275
+0.4% +$120K 0.65% 53
2020
Q4 		$26.1M Buy
1,496,525
+168,911
+13% +$3.32M 0.55% 60
2020
Q3 		$25.6M Buy
1,327,614
+7,704
+0.6% +$165K 0.65% 52
2020
Q2 		$25.7M Buy
1,319,910
+76,910
+6% +$1.29M 0.7% 53
2020
Q1 		$17.4M Sell
1,243,000
-2,000
-0.2% -$32.8K 0.72% 49
2019
Q4 		$30.5M Buy
1,245,000
+454,952
+58% +$4.85M 0.96% 39
2019
Q3 		$7.95M Buy
+790,048
New +$9.69M 0.32% 84

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rock Springs Capital Management's MIRM Position: Q2 2026 in Review

Rock Springs Capital Management reduced its Mirum Pharmaceuticals (MIRM) stake by 1.6% in Q2 2026, selling an estimated $1.32M and leaving 798,145 shares worth $93.4M. The position accounts for 4.56% of the portfolio, ranked #5.

Rock Springs Capital Management first reported a position in MIRM in Q3 2019 and has held it in 28 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Rock Springs Capital Management held 798,145 shares of Mirum Pharmaceuticals worth $93.4M as of Q2 2026.
  • Rock Springs Capital Management sold 13,149 Mirum Pharmaceuticals shares in Q2 2026, an estimated $1.32M.
  • Mirum Pharmaceuticals made up 4.56% of Rock Springs Capital Management's portfolio in Q2 2026, its #5 holding.
  • Rock Springs Capital Management first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.